DSM Pharmaceutical Products and Codexis, Inc. have signed an enzyme supply agreement granting DSM rights to use Codexis’ custom biocatalysts and services. Codexis will also supply enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM’s InnoSyn route scouting services.

Codexis technology enables development of new efficient manufacturing processes for APIs and intermediates, helping to reduce costs and environmental waste. DSM’s InnoSyn route scouting team provides solutions by integrating enzyme technology with the full range of synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry. According to the company, the new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.

“Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners,” said Joseph Sarret, M.D., president, Codexis Pharmaceutical Services & Enzyme Products. “We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale.”

Oliver May, Ph.D., corporate scientist and business manager for DSM’s InnoSyn route scouting services, said, “One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3,000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM’s capabilities to identify, develop and implement efficient enzymatic routes.”